Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)87-88
Number of pages2
JournalEvidence-Based Medicine
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2010

Cite this